660 related articles for article (PubMed ID: 24673398)
1. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
[TBL] [Abstract][Full Text] [Related]
2. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
[TBL] [Abstract][Full Text] [Related]
5. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
Gozzetti A; Fabbri A; Oliva S; Marchini E; Bocchia M; Defina M; Lauria F
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):68-72. PubMed ID: 20223732
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
[TBL] [Abstract][Full Text] [Related]
7. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
8. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
Berenson JR; Yellin O; Chen CS; Patel R; Bessudo A; Boccia RV; Yang HH; Vescio R; Yung E; Mapes R; Eades B; Hilger JD; Wirtschafter E; Hilger J; Nassir Y; Swift RA
Br J Haematol; 2011 Dec; 155(5):580-7. PubMed ID: 21950583
[TBL] [Abstract][Full Text] [Related]
9. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
Nishihori T; Baz R; Shain K; Kim J; Ochoa-Bayona JL; Yue B; Sullivan D; Dalton W; Alsina M
Eur J Haematol; 2015 Nov; 95(5):426-35. PubMed ID: 25600676
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Pantani L; Zamagni E; Zannetti BA; Pezzi A; Tacchetti P; Brioli A; Mancuso K; Perrone G; Rocchi S; Tosi P; Cavo M
Ann Hematol; 2014 Jan; 93(1):123-8. PubMed ID: 23864035
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
[TBL] [Abstract][Full Text] [Related]
12. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Xiu L; Cakana A; Parekh T; San-Miguel JF
Cancer; 2016 Jul; 122(13):2050-6. PubMed ID: 27191689
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Lantz KC; Zhuang SH; Harousseau JL; Orlowski RZ;
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):44-9. PubMed ID: 21454189
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
[TBL] [Abstract][Full Text] [Related]
17. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
[TBL] [Abstract][Full Text] [Related]
18. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
20. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
